Author:
E.I. Chukanova, A.S. Chukanova
Department of Neurology, Neurosurgery and Medical Genetics of Faculty of Faculty of Faculty of FSBEI in "RNIMU named after N.I. Pirogov »Ministry of Health of Russia, Moscow, Russia
Author:
E.I. Chukanova, A.S. Chukanova
Department of Neurology, Neurosurgery and Medical Genetics of Faculty of Faculty of Faculty of FSBEI in "RNIMU named after N.I. Pirogov »Ministry of Health of Russia, Moscow, Russia
Place of publication:
a journal of neurology and psychiatry named after S.S. Korsakova, 2019, T. 119, No. 9
Summary:
Purpose of the study. Studying the effectiveness and safety of therapy with a medicine (LP) Mexidol, used intravenously (500 mg 1 time per day) in the form of infusions for 14 days, followed by orally orally Mexidol Fort 250 in a dose of 250 mg (1 tablet) 3 times a The day for 60 days in patients with chronic ischemia of the brain against the background of arterial hypertension and atherosclerosis. Material and methods. The open observation program includes 60 patients with an established diagnosis of chronic brain ischemia, confirmed by neuroimaging research methods. Results and conclusion. The results of the study showed high efficiency and safety of sequential therapy (injections and then taking the tablet form of the LP Mexol Forte 250). Against the background of treatment, an improvement in emotional and cognitive status, a decrease in motor disorders, as well as the severity of subjective manifestations are noted. High commitment to patients to the therapy is shown. Keywords: chronic brain ischemia, arterial hypertension, atherosclerosis, ethylmethylhydroxypyrididine succinate, mexidol, cognitive disorders.
Information is intended for medical and pharmaceutical workers. This information cannot serve as a replacement for a doctor’s consultation.
Source of photos and images Shutterstock.com